BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 23207332)

  • 1. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
    Chen XF; Chen XP; Ma XJ; Chen WL; Luo XD; Liao JY
    Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB; Golge N; Akin MS
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Factors influencing the curative effect in patients with HBeAgpositive chronic hepatitis B treated with peg-interferon α-2a].
    Chen J; Zheng Q; Jiang J; Zheng J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Jul; 37(7):714-9. PubMed ID: 22886227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients].
    Huang ZL; Zhao ZX; Deng H; Zhang YF; Lu CR; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):419-22. PubMed ID: 20587310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients.
    Wang YD; Zhao CY; Wang W; Shen C; Lu HZ; Zhang L; Yu WY; Zhou JY; Yan WZ
    Hepatogastroenterology; 2012 May; 59(115):680-6. PubMed ID: 22441104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
    J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG; Lau DT; Schmid P; Perrillo R
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on the relationship between hepatitis B virus genotypes and the effect of polyethylene glycol-interferon-alpha therapy on HBeAg-positive chronic hepatitis B].
    Gao GS; Xu XZ; Hu YR; Yan HD
    Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1009-12. PubMed ID: 24503396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.